Biotech Values

[mcbio]

Galapagos held discussions with 12 potential partners for the drug, said Van de Stolpe. The company chose Abbott because “they are innovative, they’re a dominant player, and they were willing to pay premium terms.” [Unlike the CEO’s assertion earlier in this post, this one is entirely believable.]

Just another comment on this deal. Isn't ABT the partner one would want given their colossal success with Humira in the RA space? Really do think Galapagos has the right partner here. They just need to deliver on the data.